LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Search

Avita Therapeutics Inc

Fermé

5 -1.38

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.97

Max

5.03

Chiffres clés

By Trading Economics

Revenu

1.6M

-12M

Ventes

554K

18M

BPA

-0.536

Marge bénéficiaire

-65.968

Employés

226

EBITDA

1.6M

-9.7M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

-10.54% downside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

25M

149M

Ouverture précédente

6.38

Clôture précédente

5

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Avita Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 févr. 2026, 23:53 UTC

Actions en Tendance

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 févr. 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

28 févr. 2026, 21:36 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 févr. 2026, 15:20 UTC

Résultats

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

28 févr. 2026, 14:43 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 févr. 2026, 14:38 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

28 févr. 2026, 13:47 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 févr. 2026, 13:44 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

28 févr. 2026, 13:14 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 févr. 2026, 02:32 UTC

Résultats
Acquisitions, Fusions, Rachats

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

28 févr. 2026, 02:00 UTC

Acquisitions, Fusions, Rachats

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

28 févr. 2026, 02:00 UTC

Acquisitions, Fusions, Rachats

Six Months, 9 Offers and $81 Billion. How -2-

28 févr. 2026, 00:01 UTC

Acquisitions, Fusions, Rachats

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

27 févr. 2026, 23:46 UTC

Acquisitions, Fusions, Rachats

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 févr. 2026, 23:33 UTC

Acquisitions, Fusions, Rachats

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 févr. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

27 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 févr. 2026, 21:30 UTC

Résultats

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 févr. 2026, 21:30 UTC

Market Talk
Acquisitions, Fusions, Rachats

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 févr. 2026, 21:20 UTC

Acquisitions, Fusions, Rachats

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 févr. 2026, 21:17 UTC

Résultats

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 févr. 2026, 21:10 UTC

Acquisitions, Fusions, Rachats

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 févr. 2026, 21:09 UTC

Acquisitions, Fusions, Rachats

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 févr. 2026, 21:00 UTC

Résultats

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 févr. 2026, 20:31 UTC

Acquisitions, Fusions, Rachats

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 févr. 2026, 20:24 UTC

Market Talk

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 févr. 2026, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27 févr. 2026, 20:12 UTC

Market Talk

Nike Seen With Further Challenges in China -- Market Talk

27 févr. 2026, 19:44 UTC

Market Talk

Gold Caps Historic Month -- Market Talk

27 févr. 2026, 19:39 UTC

Résultats

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

Comparaison

Variation de prix

Avita Therapeutics Inc prévision

Objectif de Prix

By TipRanks

-10.54% baisse

Prévisions sur 12 Mois

Moyen 4.5 USD  -10.54%

Haut 5.5 USD

Bas 3.5 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

1

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

8.83 / 9.77Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
help-icon Live chat